Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan

Yasuhiro Fujisawa, Takeru Funakoshi, Yoshiyuki Nakamura, Maki Ishii, Jun Asai, Takatoshi Shimauchi, Kazuyasu Fujii, Manabu Fujimoto, Norito Katoh, Hironobu Ihn

Research output: Contribution to journalArticle

Abstract

Background: There are limited treatment options for advanced non-melanoma skin cancers (NMSCs). To overcome this issue, we need to conduct clinical studies, however, there is a lack of information on how many patients with advanced NMSCs are treated annually in Japan. Objective: To investigate the actual number of advanced NMSC patients in Japan. Methods: A questionnaire survey was sent to 668 institutes to educe information on: 1) the numbers of patients with squamous cell carcinoma (SCC), extramammary Paget disease (EMPD), other skin origin carcinomas, and cutaneous angiosarcoma (CAS) admitted in 2016 and 2017; 2) the preferred first- and second-line chemotherapies; and 3) the anticipated for future development. Results: Questionnaires were returned from 383 (57.3%) institutes. They reported a total of 1765 patients over the 2 years. The annual number patients with SCC, EMPD, other skin carcinomas, and CAS was 323.5, 192.5, 126, and 240.5, respectively. We estimated the annual number of patients for all 668 institutes to be 1255.6. Current first- and second-line treatment for NMSCs were chemotherapy regimens, but immune checkpoint inhibitors were the most anticipated new drugs for SCC and CAS, while chemotherapy was still the most anticipated treatment for EMPD. Conclusion: Considering that during 2017, the number of deaths in Japan due to NMSC was reported to be 948, our estimated annual number of patients with NMSCs, 1255.6 seems to be an accurate estimation. As most of the treatment options for advanced NMSCs are outdated, the results of this study should be used to propose clinical studies.

Original languageEnglish
Pages (from-to)230-236
Number of pages7
JournalJournal of Dermatological Science
Volume92
Issue number3
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Dermatology
Skin Neoplasms
Skin
Japan
Extramammary Paget's Disease
Hemangiosarcoma
Chemotherapy
Squamous Cell Carcinoma
Drug Therapy
Carcinoma
Therapeutics
Surveys and Questionnaires

Keywords

  • Advanced
  • Cutaneous angiosarcoma
  • Extramammary Paget disease
  • Incidence
  • Non-melanoma skin cancer
  • Squamous cell carcinoma
  • Treatment

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology

Cite this

Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. / Fujisawa, Yasuhiro; Funakoshi, Takeru; Nakamura, Yoshiyuki; Ishii, Maki; Asai, Jun; Shimauchi, Takatoshi; Fujii, Kazuyasu; Fujimoto, Manabu; Katoh, Norito; Ihn, Hironobu.

In: Journal of Dermatological Science, Vol. 92, No. 3, 01.12.2018, p. 230-236.

Research output: Contribution to journalArticle

Fujisawa, Y, Funakoshi, T, Nakamura, Y, Ishii, M, Asai, J, Shimauchi, T, Fujii, K, Fujimoto, M, Katoh, N & Ihn, H 2018, 'Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan', Journal of Dermatological Science, vol. 92, no. 3, pp. 230-236. https://doi.org/10.1016/j.jdermsci.2018.10.004
Fujisawa, Yasuhiro ; Funakoshi, Takeru ; Nakamura, Yoshiyuki ; Ishii, Maki ; Asai, Jun ; Shimauchi, Takatoshi ; Fujii, Kazuyasu ; Fujimoto, Manabu ; Katoh, Norito ; Ihn, Hironobu. / Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. In: Journal of Dermatological Science. 2018 ; Vol. 92, No. 3. pp. 230-236.
@article{282a252ca70c49f0982e8ea2359f905e,
title = "Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan",
abstract = "Background: There are limited treatment options for advanced non-melanoma skin cancers (NMSCs). To overcome this issue, we need to conduct clinical studies, however, there is a lack of information on how many patients with advanced NMSCs are treated annually in Japan. Objective: To investigate the actual number of advanced NMSC patients in Japan. Methods: A questionnaire survey was sent to 668 institutes to educe information on: 1) the numbers of patients with squamous cell carcinoma (SCC), extramammary Paget disease (EMPD), other skin origin carcinomas, and cutaneous angiosarcoma (CAS) admitted in 2016 and 2017; 2) the preferred first- and second-line chemotherapies; and 3) the anticipated for future development. Results: Questionnaires were returned from 383 (57.3{\%}) institutes. They reported a total of 1765 patients over the 2 years. The annual number patients with SCC, EMPD, other skin carcinomas, and CAS was 323.5, 192.5, 126, and 240.5, respectively. We estimated the annual number of patients for all 668 institutes to be 1255.6. Current first- and second-line treatment for NMSCs were chemotherapy regimens, but immune checkpoint inhibitors were the most anticipated new drugs for SCC and CAS, while chemotherapy was still the most anticipated treatment for EMPD. Conclusion: Considering that during 2017, the number of deaths in Japan due to NMSC was reported to be 948, our estimated annual number of patients with NMSCs, 1255.6 seems to be an accurate estimation. As most of the treatment options for advanced NMSCs are outdated, the results of this study should be used to propose clinical studies.",
keywords = "Advanced, Cutaneous angiosarcoma, Extramammary Paget disease, Incidence, Non-melanoma skin cancer, Squamous cell carcinoma, Treatment",
author = "Yasuhiro Fujisawa and Takeru Funakoshi and Yoshiyuki Nakamura and Maki Ishii and Jun Asai and Takatoshi Shimauchi and Kazuyasu Fujii and Manabu Fujimoto and Norito Katoh and Hironobu Ihn",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jdermsci.2018.10.004",
language = "English",
volume = "92",
pages = "230--236",
journal = "Journal of Dermatological Science",
issn = "0923-1811",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan

AU - Fujisawa, Yasuhiro

AU - Funakoshi, Takeru

AU - Nakamura, Yoshiyuki

AU - Ishii, Maki

AU - Asai, Jun

AU - Shimauchi, Takatoshi

AU - Fujii, Kazuyasu

AU - Fujimoto, Manabu

AU - Katoh, Norito

AU - Ihn, Hironobu

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: There are limited treatment options for advanced non-melanoma skin cancers (NMSCs). To overcome this issue, we need to conduct clinical studies, however, there is a lack of information on how many patients with advanced NMSCs are treated annually in Japan. Objective: To investigate the actual number of advanced NMSC patients in Japan. Methods: A questionnaire survey was sent to 668 institutes to educe information on: 1) the numbers of patients with squamous cell carcinoma (SCC), extramammary Paget disease (EMPD), other skin origin carcinomas, and cutaneous angiosarcoma (CAS) admitted in 2016 and 2017; 2) the preferred first- and second-line chemotherapies; and 3) the anticipated for future development. Results: Questionnaires were returned from 383 (57.3%) institutes. They reported a total of 1765 patients over the 2 years. The annual number patients with SCC, EMPD, other skin carcinomas, and CAS was 323.5, 192.5, 126, and 240.5, respectively. We estimated the annual number of patients for all 668 institutes to be 1255.6. Current first- and second-line treatment for NMSCs were chemotherapy regimens, but immune checkpoint inhibitors were the most anticipated new drugs for SCC and CAS, while chemotherapy was still the most anticipated treatment for EMPD. Conclusion: Considering that during 2017, the number of deaths in Japan due to NMSC was reported to be 948, our estimated annual number of patients with NMSCs, 1255.6 seems to be an accurate estimation. As most of the treatment options for advanced NMSCs are outdated, the results of this study should be used to propose clinical studies.

AB - Background: There are limited treatment options for advanced non-melanoma skin cancers (NMSCs). To overcome this issue, we need to conduct clinical studies, however, there is a lack of information on how many patients with advanced NMSCs are treated annually in Japan. Objective: To investigate the actual number of advanced NMSC patients in Japan. Methods: A questionnaire survey was sent to 668 institutes to educe information on: 1) the numbers of patients with squamous cell carcinoma (SCC), extramammary Paget disease (EMPD), other skin origin carcinomas, and cutaneous angiosarcoma (CAS) admitted in 2016 and 2017; 2) the preferred first- and second-line chemotherapies; and 3) the anticipated for future development. Results: Questionnaires were returned from 383 (57.3%) institutes. They reported a total of 1765 patients over the 2 years. The annual number patients with SCC, EMPD, other skin carcinomas, and CAS was 323.5, 192.5, 126, and 240.5, respectively. We estimated the annual number of patients for all 668 institutes to be 1255.6. Current first- and second-line treatment for NMSCs were chemotherapy regimens, but immune checkpoint inhibitors were the most anticipated new drugs for SCC and CAS, while chemotherapy was still the most anticipated treatment for EMPD. Conclusion: Considering that during 2017, the number of deaths in Japan due to NMSC was reported to be 948, our estimated annual number of patients with NMSCs, 1255.6 seems to be an accurate estimation. As most of the treatment options for advanced NMSCs are outdated, the results of this study should be used to propose clinical studies.

KW - Advanced

KW - Cutaneous angiosarcoma

KW - Extramammary Paget disease

KW - Incidence

KW - Non-melanoma skin cancer

KW - Squamous cell carcinoma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85057895180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057895180&partnerID=8YFLogxK

U2 - 10.1016/j.jdermsci.2018.10.004

DO - 10.1016/j.jdermsci.2018.10.004

M3 - Article

VL - 92

SP - 230

EP - 236

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

SN - 0923-1811

IS - 3

ER -